|
Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Exelixis; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi |
Speakers' Bureau - Bayer; Eisai; Ipsen; Merck Serono; Novartis; Pfizer; Sanofi |
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer |
|
|
Honoraria - Ipsen; Novartis |
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Merck Serono; MSD Oncology; Novartis/Ipsen; Pfizer |
Research Funding - Merck Serono (Inst); Novartis (Inst) |
|
|
Honoraria - AstraZeneca; Bayer; Eisai; Ipsen; Merck; Novartis; Pfizer; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Eisai; Ipsen; Merck; Pfizer; Roche; Sanofi; SERVIER |
Research Funding - Amgen; AstraZeneca; Bayer; Celgene; Eisai; Ipsen; Merck; Merck Sharp & Dome; Roche; Sanofi |
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Pfizer; Roche; SERVIER |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Novartis |
|
|
|
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; Genoscience Pharma; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics |
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Celgene; Nucana |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Advanced Accelerator Applications; Bristol-Myers Squibb; Celgene; Eisai; Eusa Pharma; Genzyme; IPSEN; Lexicon; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Roche |
Consulting or Advisory Role - Ipsen; MSD; Pfizer |
Research Funding - AstraZeneca (Inst); Ipsen (Inst); MTEM/Threshold (Inst); Pfizer (Inst); Roche |
|
|
Honoraria - Advanced Accelerator Applications; AstraZeneca (I); Boehringer Ingelheim (I); BRISTOL-MYERS SQUIBB; Bristol-Myers Squibb (I); Gilead Sciences (I); Ipsen; Lilly (I); MERCK; Merck (I); NOVARTIS; PFIZER; PharmaMar; PharmaMar (I); ROCHE; Roche (I); Sanofi; SERVIER; SERVIER (I); Sysmex (I) |
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis; Pfizer |
Speakers' Bureau - Ipsen; Pfizer |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Merck; Roche |
|
|
Other Relationship - IPSEN |
|
|
Consulting or Advisory Role - Amgen; Bayer; Ipsen; Merck Serono; Novartis; Roche; Sanofi/Regeneron; SERVIER |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Novartis; Roche; Sanofi/Regeneron |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen-Cilag |
Speakers' Bureau - Janssen-Cilag |
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst) |
Travel, Accommodations, Expenses - Janssen-Cilag; Sanofi; Sanofi |
|
|
Consulting or Advisory Role - Ipsen; Lilly; Novartis; Pfizer |
Travel, Accommodations, Expenses - Ipsen |
|
|
Travel, Accommodations, Expenses - Amgen; Amgen |
|
|
|
|
|
Consulting or Advisory Role - Eisai |
|